Heidelberg Pharma AG (Seite 494)
eröffnet am 26.10.17 20:25:27 von
neuester Beitrag 03.05.24 20:15:04 von
neuester Beitrag 03.05.24 20:15:04 von
Beiträge: 5.201
ID: 1.265.064
ID: 1.265.064
Aufrufe heute: 41
Gesamt: 588.338
Gesamt: 588.338
Aktive User: 0
ISIN: DE000A11QVV0 · WKN: A11QVV · Symbol: HPHA
3,0200
EUR
+1,00 %
+0,0300 EUR
Letzter Kurs 03.05.24 Tradegate
Neuigkeiten
25.04.24 · EQS Group AG |
05.04.24 · EQS Group AG |
27.03.24 · EQS Group AG |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 58.957.842 von BICYPAPA am 15.10.18 07:32:34
Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
Huizing FJ1, Hoeben BAW2, Franssen G3, Lok J2, Heskamp S3, Oosterwijk E4, Boerman OC3, Bussink J2.
Author information
Abstract
BACKGROUND AND PURPOSE:
Hypoxia is a major cause of radio- and chemoresistance. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related marker and an important prognostic marker. Assessment of CAIX expression may allow patient selection for hypoxia or CAIX-targeted treatment. The radioactive tracer 111In-girentuximab-F(ab')2 targets CAIX and can be used for SPECT imaging. Aim of this study was to validate and optimize 111In-girentuximab-F(ab')2 for imaging of CAIX expression in head and neck tumor xenografts.
MATERIAL AND METHODS:
Affinity and internalization kinetics of 111In-girentuximab-F(ab')2 were determined in vitro using CAIX-expressing SK-RC-52 cells. Tumor targeting characteristics were determined in athymic mice with six different head and neck squamous cell carcinoma (SCCNij) xenografts. Tracer uptake was measured by ex vivo radioactivity counting. Intratumoral distribution of tracer uptake was measured using autoradiography and CAIX expression was determined immunohistochemically.
RESULTS:
26% of the tracer was internalized into the SK-RC-52 cells within 24h. The half maximal inhibitory concentration (IC50) was 0.69±0.08nM. In biodistribution studies SCCNij153 tumors showed the highest tracer uptake: 4.1±0.8ID/g at 24h p.i. Immunohistochemical and autoradiographic analyses of the xenografts showed a distinct spatial correlation between localization of the tracer and CAIX expression.
CONCLUSION:
111In-girentuximab-F(ab')2 has a high affinity for CAIX. In vivo tumor uptake correlated strongly with CAIX expression in different head and neck xenografts. These results suggest that 111In-girentuximab-F(ab')2 is a promising tracer for imaging of hypoxia-related CAIX expression.
Redectane-Girentuximab_TLX250
Sehr wahrscheinlich wird die Ph3 Studie von Telix nun bald starten. Doch neben der Veröffentlichung von Telix TLX250 evtl bei Darmkrebsformen zu nutzen gibt es nun auch Hinweise Girentuximab noch in weiteren Indikationen anwenden zu können. Ich poste mal das Abstract hierzu. Das ist wahrscheinlich noch sehr langfristig. Doch es soll auch nur die Möglichkeiten von Girentuximab aufzeigen.Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
Huizing FJ1, Hoeben BAW2, Franssen G3, Lok J2, Heskamp S3, Oosterwijk E4, Boerman OC3, Bussink J2.
Author information
Abstract
BACKGROUND AND PURPOSE:
Hypoxia is a major cause of radio- and chemoresistance. Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related marker and an important prognostic marker. Assessment of CAIX expression may allow patient selection for hypoxia or CAIX-targeted treatment. The radioactive tracer 111In-girentuximab-F(ab')2 targets CAIX and can be used for SPECT imaging. Aim of this study was to validate and optimize 111In-girentuximab-F(ab')2 for imaging of CAIX expression in head and neck tumor xenografts.
MATERIAL AND METHODS:
Affinity and internalization kinetics of 111In-girentuximab-F(ab')2 were determined in vitro using CAIX-expressing SK-RC-52 cells. Tumor targeting characteristics were determined in athymic mice with six different head and neck squamous cell carcinoma (SCCNij) xenografts. Tracer uptake was measured by ex vivo radioactivity counting. Intratumoral distribution of tracer uptake was measured using autoradiography and CAIX expression was determined immunohistochemically.
RESULTS:
26% of the tracer was internalized into the SK-RC-52 cells within 24h. The half maximal inhibitory concentration (IC50) was 0.69±0.08nM. In biodistribution studies SCCNij153 tumors showed the highest tracer uptake: 4.1±0.8ID/g at 24h p.i. Immunohistochemical and autoradiographic analyses of the xenografts showed a distinct spatial correlation between localization of the tracer and CAIX expression.
CONCLUSION:
111In-girentuximab-F(ab')2 has a high affinity for CAIX. In vivo tumor uptake correlated strongly with CAIX expression in different head and neck xenografts. These results suggest that 111In-girentuximab-F(ab')2 is a promising tracer for imaging of hypoxia-related CAIX expression.
Antwort auf Beitrag Nr.: 58.987.908 von BICYPAPA am 18.10.18 04:56:44
Heidelberg Pharma: GMP-Produktion von Krebswirkstoff etabliert - Aktienanalyse
http://www.aktiencheck.de/exklusiv/Artikel-Heidelberg_Pharma…
Empfehlung
Heidelberg Pharma: GMP-Produktion von Krebswirkstoff etabliert - Aktienanalyse
http://www.aktiencheck.de/exklusiv/Artikel-Heidelberg_Pharma…
Das Abwarten der Anleger
Schmidt-Brand am 26.03. im Interview 4Investors:Wir haben unsere Investor Relations-Arbeit wieder intensiviert und halten den Kontakt zu internationalen institutionellen Investoren, die an den Fortschritten unserer Technologie interessiert sind. Wir wissen, dass es viel Arbeit und Geduld bedarf, um gerade in den USA langfristige Investoren zu gewinnen. Aber wir sind sehr optimistisch, dass wir mit guten klinischen Daten unserer innovativen Technologie neue Investoren an Bord holen können.
Antwort auf Beitrag Nr.: 58.977.369 von BICYPAPA am 17.10.18 05:15:12
Heidelberg Pharma is a drug development company, which provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
https://www.proactiveinvestors.com/companies/stocktube/10893…
Präsentation at the Bio Investor Forum
Heidelberg Pharma AG (ETR:WL6) CEO Jan Schmidt-Brand spoke with Christine Corrado at the Bio Investor Forum in San Francisco.Heidelberg Pharma is a drug development company, which provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
https://www.proactiveinvestors.com/companies/stocktube/10893…
Oder zu Höchstkursen von 2011 bei 20 Euro eingestiegen...?!
Da hilft nur nachkaufen & EK senken, Versuchsprimat! 🙈😉
Da hilft nur nachkaufen & EK senken, Versuchsprimat! 🙈😉
Trading Spotlight
Antwort auf Beitrag Nr.: 58.978.911 von versuchsprimat am 17.10.18 09:39:45
Nah mein geliebter Downpusher und Angstbeißer, schwimmen dir die guten Einsteigerkurse davon.
Eine andere Erklärung gibt es ja nicht für deine offensichtliche bauernschlaue Downpusherei.
Aber jeder wie er mag
Nah, Angst nicht mehr billig in Heidelberg Pharma rein zu kommen um nach zu kaufen...!
@versuchsprimatNah mein geliebter Downpusher und Angstbeißer, schwimmen dir die guten Einsteigerkurse davon.
Eine andere Erklärung gibt es ja nicht für deine offensichtliche bauernschlaue Downpusherei.
Aber jeder wie er mag
Kursanstieg bei minimalen Umsätzen (gestern, bisher heute)
Alte Hasen wissen, dass dies so gut wie immer nur eine rein technische Erholung ist. Zum "Schwur" kommt es deshalb noch in den nächsten Tagen. Nach der Halbierung (50 Prozent minus) bedarf es immerhin 100 Prozent plus, um den alten Kurs zu erreichen.
Antwort auf Beitrag Nr.: 58.957.842 von BICYPAPA am 15.10.18 07:32:34
Melbourne (Australia) and Nijmegen (the Netherlands) – 17 October 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has concluded a GMP manufacturing agreement with Radboud Translational Medicine B.V. (“RTM”).
Telix has been working with RTM under a technology transfer and research agreement for the past six months, during which time RTM and Telix have completed process development and production optimization. The parties are now completing validation runs with the objective of providing patient doses for European trial sites by approximately end-October 2018. Additionally, RTM will serve as a backup production site to Telix’s partner production sites in North America (Isologic) and Australia (Cyclotek).
Telix EU President Odile Jaume stated, “RTM has been a core part of taking the 89Zr-girentuximab process development out of Radboud University Medical Centre (RUMC) and industrializing the radiochemistry for Telix’s Phase III study. The RTM facility is state-of-the-art, backed by a very capable team and we are pleased to be working with them for our clinical trials and eventual commercial production of the product.”
RTM General Manager, Dr Lars Perk commented, “RUMC was a pioneer in the use of girentuximab for imaging and therapy and so it has been a pleasure to work with our university colleagues to bring this very promising technology out of academia and into a commercial production environment. As RTM continues to build its production capabilities, we welcome the opportunity to partner with innovative companies like Telix to bring new radiopharmaceuticals to market.”
Telix Redectane
Telix Selects RTM to Manufacture Kidney Imaging Program in Europe Melbourne (Australia) and Nijmegen (the Netherlands) – 17 October 2018. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has concluded a GMP manufacturing agreement with Radboud Translational Medicine B.V. (“RTM”).
Telix has been working with RTM under a technology transfer and research agreement for the past six months, during which time RTM and Telix have completed process development and production optimization. The parties are now completing validation runs with the objective of providing patient doses for European trial sites by approximately end-October 2018. Additionally, RTM will serve as a backup production site to Telix’s partner production sites in North America (Isologic) and Australia (Cyclotek).
Telix EU President Odile Jaume stated, “RTM has been a core part of taking the 89Zr-girentuximab process development out of Radboud University Medical Centre (RUMC) and industrializing the radiochemistry for Telix’s Phase III study. The RTM facility is state-of-the-art, backed by a very capable team and we are pleased to be working with them for our clinical trials and eventual commercial production of the product.”
RTM General Manager, Dr Lars Perk commented, “RUMC was a pioneer in the use of girentuximab for imaging and therapy and so it has been a pleasure to work with our university colleagues to bring this very promising technology out of academia and into a commercial production environment. As RTM continues to build its production capabilities, we welcome the opportunity to partner with innovative companies like Telix to bring new radiopharmaceuticals to market.”
Mit minimalen Umsätzen ein schönes Plus von ca. 9%.
Ich lehne mich mal aus dem Fenster uns behaupte, das war es endgültig mit Kursen unter 2 Euro, falls der Markt nicht noch mehr korrigiert. Und über kurz oder lang werden die sehr guten News der letzten Wochen eingepreist. Vielleicht auch mal ‚ne Empfehlung in einem Börsenblättchen und der Kurs läuft wieder Richtung 3 Euro (und mehr 😉)...
Ich lehne mich mal aus dem Fenster uns behaupte, das war es endgültig mit Kursen unter 2 Euro, falls der Markt nicht noch mehr korrigiert. Und über kurz oder lang werden die sehr guten News der letzten Wochen eingepreist. Vielleicht auch mal ‚ne Empfehlung in einem Börsenblättchen und der Kurs läuft wieder Richtung 3 Euro (und mehr 😉)...
Gute News sind unbedeutend, wenn Anleger die Aktie nicht mal mit spitzen Fingern anfassen
Nur der Kurs zählt. Und der liegt gerade mal doppelt so hoch wie ein Pennystock. 
Durchsuchen
25.04.24 · EQS Group AG · Heidelberg Pharma |
17.04.24 · EQS Group AG · Heidelberg Pharma |
05.04.24 · EQS Group AG · Heidelberg Pharma |
27.03.24 · EQS Group AG · Heidelberg Pharma |
27.03.24 · wO Chartvergleich · Super Micro Computer |
